title: [Treatment of premenopausal patients with advanced or recurrent breast cancer by chemical ablation].
abstract: OBJECTIVE
  To evaluate the clinical efficacy and safety of luteinizing hormone releasing hormone (LH-RH) analog in premenopausal patients with advanced or recurrent breast cancer.
  
  
  METHODS
  LH-RH analog (enantone 3.75 mg/2 ml) were administered to 28 premenopausal patients with advanced recurrent breast cancer and its efficacy and side effect were observed.
  
  
  RESULTS
  The response rate (complete response and partial response) was 42.9%, and after 8 weeks of treatment, the plasma estrogen in all patients decreased to the level of postmenopause. No major adverse events were observed.
  
  
  CONCLUSIONS
  LH-RH analog is effective and safe for premenopausal breast cancer with low adverse reaction and its administration method is easy.
authors.affiliation: Department of Surgery, PUMC Hospital, CAMS, PUMC, Beijing 100730, China. sunq63@sohu.com
authors.forename: Qiang
authors.initials: Q
authors.lastname: Sun
authors.forename: Han-yuan
authors.initials: HY
authors.lastname: Huang
authors.forename: Yi-dong
authors.initials: YD
authors.lastname: Zhou
authors.forename: Feng
authors.initials: F
authors.lastname: Mao
authors.forename: Yue-qing
authors.initials: YQ
authors.lastname: Yang
authors.forename: Ying
authors.initials: Y
authors.lastname: Xing
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D004967:Estrogens / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D017697:Premenopause
chemical_list: D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D016729:Leuprolide